Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Incyte Corporation is currently conducting a Phase 2 clinical study titled ‘A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease.’ The study aims to assess the preliminary efficacy of axatilimab combined with ruxolitinib and to evaluate axatilimab’s contribution to the treatment effect in patients with chronic graft-versus-host disease (cGVHD).
The study tests three interventions: Axatilimab combined with Ruxolitinib, Ruxolitinib alone, and Corticosteroids alone. Axatilimab and Ruxolitinib are drugs designed to treat cGVHD, with Axatilimab being the new addition under evaluation.
This interventional study is randomized with a parallel assignment. There is no masking involved, and the primary purpose is treatment-focused.
The study began on October 11, 2024, with an estimated completion date yet to be announced. The latest update was submitted on June 26, 2025, indicating ongoing recruitment.
This study update could influence Incyte’s stock performance and investor sentiment, as positive results may enhance the company’s market position in the cGVHD treatment space. Competitors in the industry will be closely monitoring these developments.
The study is ongoing, with further details available on the ClinicalTrials portal.